MADRIGAL PHARMACEUTICALS, INC. Net Income Loss

• MADRIGAL PHARMACEUTICALS, INC. showed an increase of +38.1% in Net Income Loss from 2024 to 2025.
• This data is from MADRIGAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2017: -$8.35 million | Q3 2017: -$8.36 million | Q4 2017: -$8.45 million | Q1 2018: -$6.36 million | Q2 2018: -$6.46 million | Q3 2018: -$8.51 million | Q4 2018: -$11.48 million | Q1 2019: -$15.08 million | Q2 2019: -$19.70 million | Q3 2019: -$21.43 million | Q4 2019: -$27.74 million | Q1 2020: -$36.14 million | Q2 2020: -$49.02 million | Q3 2020: -$57.96 million | Q4 2020: -$59.12 million | Q1 2021: -$52.55 million | Q2 2021: -$61.65 million | Q3 2021: -$63.10 million | Q4 2021: -$64.55 million | Q1 2022: -$57.52 million | Q2 2022: -$70.73 million | Q3 2022: -$81.20 million | Q4 2022: -$85.91 million | Q1 2023: -$76.90 million | Q2 2023: -$85.80 million | Q3 2023: -$98.74 million | Q4 2023: -$112.19 million | Q1 2024: -$147.54 million | Q2 2024: -$151.97 million | Q3 2024: -$106.96 million | Q1 2025: -$73.24 million | Q2 2025: -$42.28 million | Q3 2025: -$114.19 million.
• Over the full 10 years of available data (2016 to 2025), MADRIGAL PHARMACEUTICALS, INC.'s Net Income Loss has declined by 992.5%.
• Historical annual values: Fiscal year 2025: -$288.28 million | Fiscal year 2024: -$465.89 million | Fiscal year 2023: -$373.63 million | Fiscal year 2022: -$295.35 million | Fiscal year 2021: -$241.85 million | Fiscal year 2020: -$202.24 million | Fiscal year 2019: -$83.95 million | Fiscal year 2018: -$32.81 million | Fiscal year 2017: -$31.15 million | Fiscal year 2016: -$26.39 million.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026